R1 RCM Inc. (NASDAQ:RCM) insider Gary Steven Long sold 36,977 shares of R1 RCM stock in a transaction that occurred on Thursday, April 1st. The stock was sold at an average price of $25.04, for a total value of $925,904.08. Following the sale, the insider now directly owns 214,436 shares in the company, valued at approximately $5,369,477.44. The sale was disclosed in a document filed with the SEC, which is available at this link.
Gary Steven Long also recently made the following trade(s):
- On Monday, April 5th, Gary Steven Long sold 5,837 shares of R1 RCM stock. The stock was sold at an average price of $25.13, for a total value of $146,683.81.
R1 RCM stock opened at $24.50 on Thursday. The business’s fifty day moving average is $26.40 and its two-hundred day moving average is $22.79. The company has a debt-to-equity ratio of 8.74, a quick ratio of 1.59 and a current ratio of 1.59. The firm has a market cap of $6.40 billion, a P/E ratio of 272.25, a P/E/G ratio of 4.00 and a beta of 0.91. R1 RCM Inc. has a 52 week low of $8.34 and a 52 week high of $31.28.
A number of hedge funds have recently bought and sold shares of the stock. Barclays PLC boosted its position in R1 RCM by 9,100.0% in the 4th quarter. Barclays PLC now owns 1,656 shares of the healthcare provider’s stock valued at $40,000 after buying an additional 1,638 shares during the last quarter. USA Financial Portformulas Corp acquired a new position in shares of R1 RCM during the 4th quarter worth about $64,000. Nisa Investment Advisors LLC increased its stake in shares of R1 RCM by 53.1% in the 4th quarter. Nisa Investment Advisors LLC now owns 4,900 shares of the healthcare provider’s stock valued at $118,000 after acquiring an additional 1,700 shares during the last quarter. SG Americas Securities LLC acquired a new stake in shares of R1 RCM in the 4th quarter valued at approximately $146,000. Finally, Montag A & Associates Inc. bought a new position in R1 RCM during the 4th quarter worth approximately $192,000. Hedge funds and other institutional investors own 81.16% of the company’s stock.
RCM has been the subject of a number of recent research reports. Zacks Investment Research cut shares of R1 RCM from a “hold” rating to a “sell” rating in a research note on Wednesday, March 17th. KeyCorp increased their price target on shares of R1 RCM from $27.00 to $35.00 in a research report on Tuesday, February 16th. Cowen raised their target price on R1 RCM from $22.00 to $33.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 9th. Finally, Royal Bank of Canada boosted their price target on R1 RCM from $20.00 to $27.00 and gave the company an “outperform” rating in a research note on Wednesday, December 9th. One analyst has rated the stock with a sell rating and five have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $25.67.
About R1 RCM
R1 RCM Inc provides revenue cycle management (RCM) for healthcare providers in the United States. The company offers end-to-end RCM services to manage their revenue cycle operations that encompass patient registration, insurance and benefit verification, medical treatment documentation and coding, bill preparation, and collections from patients and payers.
Receive News & Ratings for R1 RCM Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for R1 RCM and related companies with MarketBeat.com's FREE daily email newsletter.